Login to Your Account

Financings NEWS

Pittsburgh-based Thar Pharmaceuticals Inc. is hoping to follow a similar public trajectory as one of its competitors in the complex regional pain syndrome (CRPS) space, Axsome Therapeutics Inc., which went public late last year raising about $51 million.

Cleave Biosciences Inc. has completed a $37 million series B financing to support further development of CB-5083, its lead oncology candidate for hematological and solid tumor malignancies and discovery efforts related to its AAA ATPase platform over the next 18 months.

After seeding gene therapy start-up Avrobio Inc. earlier this year, Atlas Venture stepped back up to the plate, joined by Clarus and SV Life Sciences, to fund the company’s $25 million series A.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: